From: Disease course and treatment effects of a JAK inhibitor in a patient with CANDLE syndrome
Date | Age | Leucocytes ×109/L | Neutrophils ×109/L | CRP mg/L |
---|---|---|---|---|
June 2015 | 2 y 10 mo | 8.27 | 7.51 | 114.09 |
April 2016 | 3 y 8 mo | 16.62 | 11.01 | 23.71 |
November 2016 | 4 y 3 mo | 16.12 | 12.16 | 16.3 |
January 2017 | 4 y 5 mo | 10.81 | 9.11 | 76.18 |
March 2017 | 4 y 7 mo | 10.89 | 5.12 | 43.04 |
Start of Baricitinib in August 2017 | ||||
September 2017 | 5 y 0 mo | 16.88 | 12.24 | 2.8 |
October 2017 | 5 y 2 mo | 8.73 | 3.5 | 0.13 |
December 2017 | 5 y 4 mo | 7.66 | 3.53 | 8.78 |
February 2018 | 5 y 5 mo | 7.89 | 4.47 | 17.13 |
April 2018 | 5 y 7 mo | 6.74 | 2.78 | 7.48 |
February 2019 | 6 y 5 mo | 7.5 | 5.79 | 18.63 |